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Abstract 
Following injury, the tissue plasminogen activator (tPA) is upregulated to maintain tissue 
hemostasis through its main product, plasmin. However, many reports have shown that tPA 
can act as a cytokine by itself and exerts many effects controlling cell fate. Therefore, we 
investigated its role in modulating one of the main cellular components of the bone marrow 
niche, the mesenchymal stem cells. In this study, we demonstrate that tPA expands murine 
bone marrow-derived CD45- TER119- Sca-1+ PDGF-Rα+ mesenchymal stem cells (MSCs) in 
vivo through a crosstalk with endothelial cells. Mechanistically, by driving conversion of 
plasminogen into plasmin, tPA activates matrix metalloproteinases (MMPs). In turn, ….These 
data show a novel mechanism to expand the pro-homeostasis MSCs in vivo which can arguably 
lead to faster recovery following injury. 
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Introduction 
I. The fibrinolytic/protease pathway: tissue plasminogen activator and MMPs 
Tissue injury leads to the activation of the coagulation system resulting in thrombus formation 
by thrombin. The fibrinolytic system with its main player, plasmin, degrades fibrin within the 
thrombus. Plasmin is a serine protease generated by the conversion of plasminogen (Plg) by 
the tissue and urokinase plasminogen activators (tPA and uPA, respectively), and kallikrein.  
tPA consists of 527 amino acids containing 5 domains: a fibronectin-like finger, an epidermal 
growth factor-like cassette, two kringle structures and a serine protease domain. Plasmin 
converts tPA from a single-chain tPA to a more active two-chain polypeptide by the cleavage 
of the Arg275-Ile276 peptide bond (Pennica et al, 1983). Endothelial cells lining up veins and 
arteries are the main source of tPA. Several stimuli regulate the gene expression of tPA and its 
release such as thrombin, adrenaline, histamine and arterial shear stress level. tPA activity is 
inhibited by its endogenous inhibitors: plasminogen activator inhibitor -1 (PAI-1) and PAI-2. 
PAI-1, which is the most potent inhibitor of tPA, is synthesized by platelets, endothelial and 
hepatic cells and its expression is regulated by thrombin and growth factors like the 
transforming growth factor beta (TGF-ß), proinflammatory cytokines such as tumor necrosis 
factor-α and ﬁbroblast growth factor-2 (FGF-2) (Hajjar, 2003). PAI-1 exists in the blood (2µM) 
in both active and latent form accounting for 90% of circulating PAI-1. It also exists bound to 
the extracellular matrix (ECM) in an active form that can be released upon binding to 
plasminogen activators (PAs). Hence, this reservoir of matrix-bound PAI-1 is essential to 
rapidly neutralize tPA which is known to have a very short half-life of 5 minutes (as for human 
endogenously occurring tPA) and is accumulated in the liver and rapidly cleared from the blood 
system. Many mutant proteins have been engineered to increase the half-life of tPA leading to 
an up to 50 minutes half-life (Gerard and Meidell., 1989).  
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The Plg/plasmin cascade and matrix metalloproteinases (MMPs) can induce extracellular 
proteolysis that is critical for development, tissue repair, and the control of stem cells. They are 
essential players in physiological events like inflammation, angiogenesis. Plasmin can catalyze 
the activation/inactivation of cytokines, chemokines, cell surface receptors, growth factors and 
other proteases like (MMPs) which, together with plasmin can accelerate local ECM 
degradation thus leading to its remodeling and the release of ECM-bound signaling molecules 
(Cauwe et al., 2007; Heissig et al., 2012). The Plg/plasmin cascade is depicted in the diagram 
below (Diagram 1). MMPs, synthesized as zymogens, are a large family of zinc-dependent 
endoproteinases. The enzymatically inactive state of MMPs is due to the interaction of the 
cysteine residue of the pro-domain with the zinc ion localized in the catalytic site. Therefore a 
cysteine switch is required for their activation. MMPs are activated by the removal of the pro-
domain by furin, other MMPs or serine proteinases like plasmin. In total, there are 23 MMPs 
in humans that, according to their structure, can be organized into 4 different groups including 
gelatinases. MMP-2 and MMP-9 are two types of gelatinases constitutively expressed by many 
cells including the fibroblasts and endothelial cells. Thanks to their fibronectin catalytic domain, 
these gelatinases are able to degrade a broad spectrum of ECM components such as collagen 
type I, IV, V, X, fibronectin, elastin, aggrecan and laminin as well as activating several growth 
factors including TNF-α, TGF-ß and IL-1ß (Werb, 1997; Kessenbrock et al., 2010). 
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Diagram1: The fibrinolytic system; Adopted from CoaguCheck® (Roche) 
Several genetic knockout models have been created and helped to understand the role of 
fibrinolytic factors and MMPs in many physiological events as well as during development and 
disease. Below is a summary of few established models: 
Genotype Phenotype 
Plg -/- Spontaneous thrombosis, runting, premature death; Fibrin in liver, lungs, 
stomach; Gastric ulcers; Impaired wound healing; Ligneous conjunctivitis; 
Impaired monocyte recruitment; Impaired neointima formation after 
electrical injury; Impaired dissemination of Borrelia burgdorferi; Reduced 
excitotoxic neuronal cell death in brain 
tPA -/- Reduced lysis of fibrin clot; Increased endotoxin-induced thrombosis  
uPA -/- Occasional fibrin in liver/intestine; Rectal prolapse, ulcers of eyelids, face, 
ears; Reduced macrophage degradation of fibrin; Increased endotoxin-
induced thrombosis 
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uPA-/-/ 
tPA-/- 
Reduced growth, fertility and lifespan; cachexia; Fibrin deposits in liver, 
gonads, lungs; Ulcers in intestine, skin, ears; rectal prolapse; Impaired clot 
lysis 
PAI -/- Mildly increased lysis of fibrin clot; Resistance to endotoxin-induced 
thrombosis 
MMP2 -/- Reduced body size; reduced neovascularization; decreased primary ductal 
invasion in the mammary gland; reduced lung saccular development 
MMP9 -/- Bone-development defects; defective neuronal remyelination after nerve 
injury; delayed healing of bone fractures; impaired vascular remodelling; 
impaired angiogenesis 
 
Table 1: Selected fibrinolytic factors and MMP mutant phenotypes; Adopted from 
Cesarman-Maus and Hajjar., 2005; Page-McCaw et al., 2007 
      II. The role of fibrinolytic factors in the Bone Marrow (BM) 
Hematopoiesis is the process by which all blood cells are generated from a small pool of 
multipotent hematopoietic stem cells (HSC). These cells exist in the BM during adulthood in a 
quiescent state and are induced to proliferate and differentiate following hematological stress 
like bleeding, irradiation or chemotherapy in order to regenerate injured tissues. This process 
is tightly controlled by a specific microenvironment in the BM called the BM niche that 
consists of the ECM and a plethora of stromal cells and non-hematopoietic cells like endothelial 
cells, osteoblasts and fibroblasts (Morrison and Scadden, 2014).  
MMPs like MMP-9 were shown to be essential for BM regeneration following 
myelosuppression by the 5-fluorouracil (5-FU) drug as mice deficient in MMP-9 showed a 
lower survival rate due to a delayed hematopoietic recovery (Heissig et al., 2002). Moreover, 
an accumulation of plasminogen/plasmin and an upregulation in tPA was observed in the BM 
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stromal compartment following myelosuppression. Plasminogen was also shown to be 
important for hematopoietic recovery because Plg deficient mice could not survive the 
myelosuppression due to a failure in cell cycle activation of dormant HSCs (Heissig et al., 
2007). Mechanistically, it was shown that Plg effect was mediated through the activation of 
MMP-9 and the release of the hematopoietic maintenance factor kit ligand (KitL; also known 
as stem cell factor/SCF). Several studies have shown that the lack of the membrane form of 
KitL impairs hematopoiesis (Brannan et al., 1991). Initially it was suggested that KitL is 
secreted by many cell types of the BM like stromal cells, but a recent study demonstrated that 
endothelial cells and perivascular mesenchymal stem cells are the main source of KitL (Ding 
et al., 2012).  
 
III. Mesenchymal Stem Cells: 
Mesenchymal stem cells (MSCs) are a subset of BM stromal cells that have a prominent role 
in local tissue remodeling and regeneration. MSCs were first identified by Friedenstein in the 
early 70’s (Friedenstein et al., 1974). They were isolated from BM and characterized as 
fibroblast-like shaped cells, able to form colonies in vitro (colony forming unit-fibroblast, 
CFU-F) and showed multipotency, i.e. the ability to differentiate into different mesenchymal 
tissues including osteoblasts, adipocytes and chondrocytes, as well as hematopoietic stromal 
cells (Horwitz et al., 2005; Bianco et al., 2008). They are a rare population of cells forming 
only 0.001%- 0.01% of the human adult BM cells (Pittenger et al., 1999) and are mainly 
perivascular (Crisan et al., 2008). 
Other than the BM, MSCs virtually exist in every type of connective tissue such as fat (Zuk et 
al., 2001), muscle (Poulsom et al., 2002), skin (Toma et al., 2001) and placenta (Fukuchi et al., 
2004). 
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MSCs are further characterized by the lack of expression of endothelial and hematopoietic 
markers (e.g. CD45, Ter119, CD31) and a positive expression of mesenchymal markers like 
CD146 for human BM MSCs (Sacchetti et al., 2007) or Nestin (Mendez-Ferrer et al., 2010), 
Leptin receptor (Zhou et al., 2014), Platelet-Derived Growth Factor Receptor α (PDGFRα) and 
Stem cell antigen-1 (Sca-1) for mouse (Morikawa et al., 2009). Although the origin and 
relationship between these recently reported subpopulations of MSCs remain unclear, they all 
showed the common potential of supporting hematopoiesis in vivo by generating a stromal cell 
niche important for HSC maintenance.  
Many techniques have been developed in order to prove the true functional properties of MSCs, 
like their ability for self-renewal and differentiation. When transplanted in vivo, these cells can 
generate a bone organoid composed of bone, fat, cartilage and hematopoietic stroma that allows 
HSCs of the recipient mouse to home to and to engraft, thus forming a site of extramedullar 
hematopoiesis (Bianco, 2014). 
MSCs offer many advantages in the field of autologous cell therapies thanks to their 
immunomodulatory potential, low immunogenicity and homing capacity to sites of injury (Wei 
et al., 2013). Even though they are easy to isolate, their low numbers in the adult BM hinders 
their use in the clinic. Moreover, MSCs fate is dictated by external signals from the 
microenvironment through cell-cell and cell-matrix interactions which are hardly replicated in 
vitro, making the expansion of true MSCs ex vivo a difficult process (Liechty et al., 2000). 
Therefore, finding a mechanism by which MSCs can be expanded in vivo is of utmost 
importance.  
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Hypothesis 
The fibrinolytic system is activated under stress situations like ischemia, myelosuppression, or 
during cancer growth (Heissig et al., 2007; Ohki et al., 2010; Tashiro et al., 2012). Previously, 
we reported that tPA is upregulated following myelosuppression resulting in hematopoietic 
regeneration through KitL release which results in hematopoietic stem cells (HSCs) activation 
and cell cycle entry (Heissig et al., 2007). Many other studies have addressed the importance 
of several cell types in creating a specialized hematopoietic microenvironment, or niche, which 
will ensure the maintenance and proliferation of HSCs. A recent study has shown that the 
ablation of perivascular Nestin-expressing mesenchymal stem cells (MSCs) reduces the HSCs 
number in the BM and impairs their homing upon transplantation (Mendez-Ferrer et al., 2010). 
Although, plasmin or MMPs have already been shown to direct BM regeneration and that 
MSCs are also important for BM maintenance, no studies have yet characterized how plasmin 
or MMPs can influence other BM niche cells like the stromal MSCs. Therefore, it is important 
to understand how the fibrinolytic/ protease systems regulate other niche cells. 
Here, we hypothesize that plasmin in part by modulating MMPs can influence MSCs fate i.e. 
proliferation and differentiation.  
 
 
 
 
 
 
9 
 
Material and Methods 
Experimental Animals 
C57BL/6 (WT B6) mice were purchased from SLC. WT tissue-type plasminogen activator 
(tPA)+/+ and knockout tPA (tPA-/-), plasminogen (Plg) +/+, Plg-/-, plasminogen activator 
inhibitor-1 (PAI-1)+/+, PAI-1 -/-, matrix metalloproteinase-9 (MMP9+/+) and MMP9-/- mice were 
used after more than 10 back crosses onto a C57BL/6 background. Animal procedures were 
approved by the Experimental Animal Care and Use Committee in the Animal Review Board 
of Institute of Medical Science, University of Tokyo.  
 
In vivo treatment regiments 
 
Blocking experiments in vivo:  
 
Preparation of bone marrow mesenchymal stem cells 
MSCs were prepared as previously described (Morikawa et al., 2009): The bone fragments 
were collected from femurs and tibias and incubated for 1h at 37°C in 20ml of DMEM 
(Invitrogen) containing 40mg collagenase (Wako Chemicals, Inc.), 10mM Hepes (pH7.2) and 
1% Penicillin/Streptomycin with gentle shaking. The cell suspension was filtered with a cell 
strainer (BD Falcon 2350, 70m mesh) to remove debris and bone fragments and centrifuged 
at 1200 rpm for 7 min at 4°C. The pellet was resuspended into 1ml of cold sterile water for 5 
to 10 s to lyse the red blood cells, followed by addition of 1ml of cold 2x PBS containing 4% 
FBS. The suspension was filtered through a cell strainer and centrifuged again. The pellet was 
resuspended in 1ml of ice-cold HBSS/2%FBS and stained for 30 min with the following mAbs: 
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APC-conjugated PDGFR (APA5), FITC-conjugated Sca-1 (Ly6A/E), Pacific blue-
conjugated CD45 (30-F11) and PE-TER119 (TER-119). All mAbs were purchased from 
eBioscience. 
Another set of antibodies was used to identify the LeptinR+ MSC subpopulation: FITC-
conjugated CD31+ (PECAM-1) and biotinylated LeptinR (R&D systems, BAF497) which was 
visualized with APC-conjugated streptavidin (Invitrogen). 
Flow cytometry analysis and sorting were performed on a FACS Verse and Area (BD 
Biosciences) flow cytometers. PI fluorescence was measured, and PI positive cells (dead cells) 
were excluded.  
Femoral muscle and subcutaneous fat were similarly collagenase-digested and single cells were 
stained similarly. 
 
Cell cycle analysis 
 5x106 MSCs were suspended in warm medium at 106 cells/ml and mixed with Hoechst 33342 
(Dojindo, Japan) at 10µg/ml. Verapamil was added at 40µg/ml to block dye flux. Cells were 
incubated for 40min at 37°C with occasional shaking. Pyronin Y (Sigma-Aldrich) was added 
at 0.5µg/ml. Cells were incubated for 20min, centrifuged and resuspended in FACS buffer for 
subsequent flow cytometry analysis. 
 
Colony forming Unit-Fibroblast assay 
To determine the clonogenic potential of MSCs, single cells from MSCs suspension were 
plated in a 96-well plate by FACS sorter (Aria, BD Biosciences) and maintained in MSCs 
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growth medium (10% fetal bovine serum in MEM GlutaMAX, Gibco) for 2 weeks. Adherent 
visible colonies (more than 50 cells) were counted under a microscope. 
 
Differentiation cultures  
To induce adipogenic differentiation, confluent cells were cultured for 2 days, replaced with 
Adipogenic Induction Medium for 2 days followed by Adipogenic Maintenance Medium 
(Lonza) for 4 days, supplemented with 1.7μM (1μg/ml) insulin, 0.25μM dexamethazone (DEX) 
and 1mM isobuthylmethylxisantin (IBMX). Medium was changed every other day. After 8 
days, the cells were fixed with 4% paraformaldehyde for 15min, and stained with Oil Red O 
(MutoPure Chemicals). 
For chondrogenic differentiation, cultured cells were harvested by trypsinization. The 1~2.5 
x105 cells were washed with MEMα + GlutaMAX (Invitrogen). The tube was spun at 150x g 
for 5min at room temperature and the supernatant was aspirated. The cells were resuspended 
in 1ml Differentiation Basal Medium Chondrogenic (Lonza), spun at 150x g for 5 min, and the 
medium was aspirated. The cells were resuspended in 1ml of Differentiation Basal Medium 
Chondrogenic, supplemented with Chondrogenic SingleQuots kit, TGF-3 (10ng/ml; Lonza) 
and BMP-6 (500ng/ml; R&D Systems), and spun at 150x g for 4min, 300 x g for 4min, and 
450x g for 4min at room temperature. The pellet was maintained with Differentiation Medium 
changed every 2 days for 2-3 weeks. After 3 weeks, cell clumps were harvested, washed in 4% 
paraformaldehyde, and their tissue sections were stained with Toluidine Blue (Sigma-Aldrich). 
To induce osteogenic differentiation, subconfluent cells were cultured with differentiation 
Basal Medium Osteogenic, supplemented with Osteogenic SingleQuots (Lonza) for 8 days. 
The cells were then fixed with 4% paraformaldehyde for 15min and stained with Alizarin Red 
S (Sigma-Aldrich). 
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Cell cultures 
MSC single cell cultures: Isolated CD45- Ter119- Sca-1+PDGFR+ cells were cultured in 10% 
FBS/ MEMα/ Glutamax medium. Cells were passaged by trypsinization every 3 days. Cells 
from 2-10 passages were used for analysis. 
Endothelial single cell cultures: Both murine and human endothelial cells (ECs) were used in 
this study: Magnetic-Activated Cell Sorting (MACS)-isolated murine CD45-CD31+ ECs and 
human umbilical vein endothelial cells (HUVECs; purchased from Gibco) were cultured at 
37°C and 5% CO2 on 0.1% gelatin (Wako Pure Chemicals, Tokyo Japan)-coated plastic culture 
plates (Falcon) in EGM-2 medium (Lonza, cc4176). 
Cytokine treatment of cultured cells:  
 
Transwell cultures 
  
MSC proliferation assay 
CD45- Ter119- Sca-1+PDGFR+ MSCs (5000 cells/well) were cultured for 3 days in 96-well 
plate with MSC growth medium in triplicate. Culture medium was changed once and replaced 
with Cell Counting Kit-8 containing fresh medium (x20 dilution, 100l) (Dojin-Wako Pure 
Chemical, Tokyo, Japan). Cells were cultured for an additional 1-2h. The absorbance at 450 
nm was measured by an ELISA plate reader (Molecular Devices, microplate reader with 
SoftMax Pro, Tokyo, Japan).  
BrdU assay: FACS-sorted PαS-MSCs derived from control and tPA-treated mice were 
analyzed using BrdU Cellomics® proliferation kit (Thermo Scientific). Cells were fixed, 
permeabilized and stained according to manufacturer’s instructions. Ten images/group were 
analyzed using a fluorescent microscope. 
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Quantitative RT-PCR Analysis 
Total RNA was prepared from cell pellets using TRIzol Reagent (Ambion by Life 
Technologies, #15596018) according to the manufacturer's instructions. First-strand cDNA 
was synthesized from 0.2-2μg of total RNA using a High Capacity Reverse Transcriptase kit 
(Applied Biosystems). The cycle number for PCR was 40 for all samples using a qPCR 
machine Step One Plus (Applied Biosystems) with SYBR Premix Ex Taq II (x2) Tli RNaseH 
Plus (Takara, #RR820). Primer sequences are provided in annex.  
RTK array 
In order to determine the activated tyrosine kinase receptors in MSCs following tPA treatment, 
MSCs were sorted from PBS or tPA treated mice and cultured for 6h in 6 well plates at a cell 
density of 5 x 104 cells/well. Medium was changed and cells were cultured for another 24h. 
Then cells were lysed and analyzed using RTK array kit according to the manufacturer's 
protocol (R&D systems, #ARY014). The band intensity was measured using an Epson scanner 
and analyzed using ImageJ.  
 
Western blot analysis 
Cultured cells were lysed with ice-cold 1% TritonX-100 buffer (20 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 1% TritonX-100 w/v, 2mM EDTA, 1mM Na3VO4, 10mM NaF) and 1mM PMSF 
(added freshly) for 10min on ice. Remaining supernatants were centrifuged at 15,000rpm for 
10min at 4°C, and supernatants were collected. The cell lysates (2~50μg proteins) were applied 
on 8% or 10% acrylamide gel, transferred to a PVDF membrane (Millipore, Immobilon), 
blocked with 5% skim-milk in PBST (PBS containing 0.05% Tween20), and stained overnight 
at 4°C with antibodies. Membranes were stained with secondary antibody conjugated with 
horse radish peroxidase (Nichirei, rabbit-HRP or goat-HRP), and developed with the ECL Plus 
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detection system (Amersham Life Science, RPN2132) using image analyzer Image-Quant 
LAS4000 (GE-healthcare).  
 
ELISA 
Mouse serum and plasma taken at indicated time points were used for ELISA analysis 
according to the manufacturer's protocol. 
 
Immunohistochemistry 
Mouse femur samples were snap frozen with Tissue-Tek OCT Compound (Sakura) in liquid 
nitrogen. Transverse tissue sections of the whole femur were prepared. Tissue sections were 
blocked with BSA/serum buffer (5% BSA and 5% normal goat serum in PBS(-), pH 7.2), and 
stained with the primary antibodies (1μg/ml solved in BSA/serum buffer) overnight at 4°C. 
Respective mouse, rat, and rabbit IgG (Santa Cruz Biotsch) isotype controls followed by 
Alexa488 or Alexa594-conjugated secondary antibodies (IgG H+L) (Invitrogen, A11072, 
A11017). Nuclei were counterstained with DAPI (Molecular Probes). Immunoreactions were 
visualized with the use of an Olympus fluorescence microscope IX71 and BX51.  
 
Gelatin-based Zymography 
To determine MMP activity in plasma or culture samples, 1 mL cell culture of culture 
supernatants or 10µl of plasma (+990µl PBS) was mixed with 20 μL gelatin-agarose beads 
(Sigma-Aldrich, G5384) and incubated overnight at 4°C. Samples were run through SDS-
PAGE acrylamide gels containing 1% gelatin. Gels were subsequently incubated in renaturing 
buffer (1M Tris-HCl, 10% NaCl, 2.5% Triton X-100) for 2 hours at room temperature, rinsed 
in distilled water and placed in low-salt collagenase buffer (5% Tris-HCl, 1% CaCl2) at 37°C 
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for 24 hours. Gels were stained with 0.2% Coomassie blue solution for 30min, and then 
destained in bleaching solution (DW, 5% methanol and 7% acetic acid) until bands are clear. 
The density of each lytic band was quantified using image analysis software (ImageJ). 
 
Plasmin concentration assay 
Plasma samples were incubated with thrombin (1U/ml) and fibrinogen (5mg/ml) at 37°C for 
30min then put on ice for 2 minutes. Samples were centrifuged at 15,000rpm for 5min. 
Supernatants were recovered and protein content (which is the result of product degradation by 
plasmin) was measured at 280nm. 
 
Knockdown experiments in B16F10 melanoma 
 
Statistical analysis 
Results are presented as means ±SEM. Statistical comparisons were based on Student’s t test 
or ANOVA with Tukey HSD posthoc tests using R program. P value level of <0.05 was 
considered significant.  
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